menu
    • menu
    [{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tilmanocept","moa":"CD206","graph1":"Oncology","graph2":"Phase IV","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Norgine","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.26000000000000001,"dosageForm":"Capsule","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Covis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Oncology","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Fennec Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Norgine","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Theravia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cytotoxic Drug","year":"2025","type":"Acquisition","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Theravia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cytotoxic Drug","year":"2025","type":"Acquisition","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dantrolene","moa":"Ryanodine receptor 1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||Solute carrier family 12 member 1 (SLC12A1)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NRL994","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Norgine

    Menu

    Norgine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyurea

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Theravia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Norgine completes acquisition of Theravia

                            Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.

                            Product Name : Siklos

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            August 14, 2025

                            Lead Product(s) : Hydroxyurea

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Theravia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Norgine gets Australia TGA Approval for IFINWIL in High-Risk Neuroblastoma

                            Details : Ifinwil (eflornithine) is a TGA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                            Product Name : Ifinwil

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            April 17, 2025

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyurea

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Theravia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Norgine Strengthens Rare Disease Portfolio with Acquisition of Theravia

                            Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.

                            Product Name : Siklos

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            April 15, 2025

                            Lead Product(s) : Hydroxyurea

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Theravia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : $260.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            X4 Pharmaceuticals, Norgine Sign License for Mavorixafor in Europe, Australia

                            Details : Under the licensing agreement, Norgine will hold exclusive rights to commercialize Xolremdi (mavorixafor) in Europe, Australia, etc. It is being indicated for the treatment of WHIM syndrome.

                            Product Name : Xolremdi

                            Product Type : Miscellaneous

                            Upfront Cash : $29.1 million

                            January 13, 2025

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : $260.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Norgine Submits DFMO Marketing Application to EMA for Neuroblastoma

                            Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                            Product Name : Iwilfin

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRL001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days

                            Details : NRL001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fecal Incontinence.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : NRL001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRL001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Dose Response to Single Anal Doses of NRL001

                            Details : NRL001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fecal Incontinence.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : NRL001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRL994

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution

                            Details : NRL994 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : NRL994

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Norgine Submits MAA for Eflornithine in High-Risk Neuroblastoma via Project Orbis

                            Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                            Product Name : Iwilfin

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            April 15, 2024

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dantrolene

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Norgine Receives Positive ChMP Opinion for NPJ5008 for Treating Malignant Hyperthermia

                            Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Dantrolene

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth